drugset / Trial / NCT00203060

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

NCT00203060

Phase 3 Completed 404 enrolled Teva Neuroscience, Inc.
RandomizedParallel-groupDouble-blind

Summary

Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.

Timeline

Start
1997-07
Primary completion
2000-07
Completion
2000-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 1 mg
Subject Rasagiline Small molecule 2 mg

Indications